Salah-Eddin Al-Batran, MD, medical oncologist and director at the Institute of Clinical Cancer Research—Frankfurt, Germany, discusses the future of treatment in gastric cancer.

Immunotherapies continue to show promise in this landscape, with the results of the ONO-4538-12 trial demonstrating the activity of nivolumab (Opdivo) in patients with unresectable advanced or recurrent gastric cancer.

Al-Batran says that the emergence of these new agents in immunotherapy will hopefully improve survival in this disease.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Immuno-Oncology

Salah-Eddin Al-Batran, MD, medical oncologist and director at the Institute of Clinical Cancer Research&mdash;Frankfurt, Germany, discusses the future of treatment in gastric cancer.

Dr. Al-Batran on Future of Treatment in Gastric Cancer